Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-25-019659
Filing Date
2025-04-24
Accepted
2025-04-24 16:03:12
Documents
22
Period of Report
2025-06-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A bcrx-20250424.htm   iXBRL DEF 14A 1211252
6 bcrx-20250424_g1.jpg GRAPHIC 22227
7 bcrx-20250424_g2.jpg GRAPHIC 134096
8 bcrx-20250424_g3.jpg GRAPHIC 115480
9 bcrx-20250424_g4.jpg GRAPHIC 125548
10 bcrx-20250424_g5.jpg GRAPHIC 155425
11 bcrx-20250424_g6.jpg GRAPHIC 114420
  Complete submission text file 0001628280-25-019659.txt   3513020

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcrx-20250424.xsd EX-101.SCH 2355
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcrx-20250424_def.xml EX-101.DEF 2391
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcrx-20250424_lab.xml EX-101.LAB 2738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcrx-20250424_pre.xml EX-101.PRE 1472
24 EXTRACTED XBRL INSTANCE DOCUMENT bcrx-20250424_htm.xml XML 108522
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-23186 | Film No.: 25867194
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)